It is known that KRAS, p16/DCKN2A, GNAS, and BRAF are mutated early in pancreatic cancer progression, while SMAD4/DPC4 and TP53 are mutated at later stages [25, 46]. This evidence concerns the gene KRAS and pancreatic neoplasm.